

## MGFA Post-intervention Status (MGFA-PIS)

<b>Complete Stable Remission (CSR)</b>	The patient has had no symptoms or signs of MG for at least 1 year and has received no therapy for MG during that time. There is no weakness of any muscle on careful examination by someone skilled in the evaluation of neuromuscular disease. Isolated weakness of eyelid closure is accepted.
<b>Pharmacologic Remission (PR)</b>	The same criteria as for CSR except that the patient continues to take some form of therapy for MG. Patients taking cholinesterase inhibitors are excluded from this category because their use suggests the presence of weakness.
<b>Minimal Manifestations (MM)</b>	The patient has no symptoms of functional limitations from MG but has some weakness on examination of some muscles. This class recognizes that some patients who otherwise meet the definition of CSR or PR do have weakness that is only detectable by careful examination.
<b>MM-0</b>	The patient has received no MG treatment for at least 1 year.
<b>MM-1</b>	The patient continues to receive some form of immunosuppression but no cholinesterase inhibitors or other symptomatic therapy.
<b>MM-2</b>	The patient has received only low-dose cholinesterase inhibitors (<120 mg pyridostigmine/day) for at least 1 year.
<b>MM-3</b>	The patient has received cholinesterase inhibitors or other symptomatic therapy and some form of immunosuppression during the past year.
<b>Change in Status Improved (I)</b>	A substantial decrease in pretreatment clinical manifestations or a sustained substantial reduction in MG medications as defined in the protocol. In prospective studies, this should be defined as a specific decrease in QMG score.
<b>Unchanged (U)</b>	No substantial change in pretreatment clinical manifestations or reduction in MG medications as defined in the protocol. In prospective studies, this should be defined in terms of a maximum change in QMG score.
<b>Worse (W)</b>	A substantial increase in pretreatment clinical manifestations or a substantial increase in MG medications as defined in the protocol. In prospective studies, this should be defined as a specific increase in QMG score.
<b>Exacerbation (E)</b>	Patients who have fulfilled criteria of CSR, PR or MM but subsequently developed clinical findings greater than permitted by these criteria.
<b>Died of MG (D of MG)</b>	Patients who died of MG, of complications of MG therapy or within 30 days after thymectomy.